The use of glucagon-like peptide-1 (GLP-1) agonists, such as semaglutide and tirzepatide, has recently gained significant public attention for their efficacy in treating obesity and promoting weight loss [1,2]. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.